NDA 021287 · Advanz Pharma
Uroxatral
Alfuzosin Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: May 22, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jun 12, 2003
Approved uses
2
Original approval plus efficacy supplements
Registered trials
46
18 Phase 3, 0 recruiting
FAERS reports
3,374
1,950 serious, 242 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2024.
UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. ( 1 ) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. ( 1.1 ) UROXATRAL is not indicated for use in the pediatric population. ( 1.1 , 8.4 , 12.3 ) 1.1 Important Limitations of Use UROXATRAL is not indicated for the treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population.
Mechanism: Alfuzosin is a selective antagonist of post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 15, 2010 Supplement 16 · Efficacy · priority review LetterPediatric Written RequestPediatric Amendment 1
- Jun 12, 2003 Original approval · Type 1 - New Molecular Entity NovelReviewLabelLetter
1 products under this application
- UROXATRAL · ALFUZOSIN HYDROCHLORIDE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Alfuzosin" as an intervention, any sponsor and status, largest first.
- Clinical Trial in Males With BPH (Enlarged Prostate)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00029822 · 1,522 participants · Start May 2001
Drug: Alfuzosin (SL770499) · For: Urinary Retention; Prostatic Hyperplasia; Benign Prostatic Hypertrophy
Sites: Huntsville, Alabama; La Mesa, California; San Bernardino, California · 54 sites in all
- Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic HyperplasiaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00399464 · 1,177 participants · Start Nov 2006 · Primary completion Oct 2007
Drug: alfuzosin · For: Prostatic Hyperplasia
Sites: Tokyo, Japan
- ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPHPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00290030 · 800 participants · Start May 2001 · Primary completion Oct 2004
Drug: Alfuzosin · For: Prostatic Hyperplasia; Acute Urinary Retention
- Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic HyperplasiaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00409357 · 473 participants · Start Nov 2004 · Primary completion Aug 2005
Drug: SL77.0499-10 (alfuzosin hydrochloride) · For: Benign Prostatic Hyperplasia
Sites: Tokyo, Japan
SanofiSanofi (SNY)
NCT00486785 · 431 participants · Start Apr 2006 · Primary completion Oct 2007
Drug: Alfuzosin · For: Prostatic Hyperplasia
Sites: Bogotá, Colombia; Quito, Ecuador; Guatemala City, Guatemala · 4 sites in all
SanofiSanofi (SNY)
NCT00540891 · 372 participants · Start Feb 2003
Drug: ALFUZOSIN · For: Benign Prostatic Hyperplasia
Sites: Bridgewater, New Jersey
SanofiSanofi (SNY)
NCT00941343 · 362 participants · Start Sep 2006 · Primary completion Sep 2008
Drug: Alfuzosin (XATRAL® - SL770499) · For: Prostatic Diseases
Sites: Taipei, Taiwan
- Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain SyndromePivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00103402 · 272 participants · Start Feb 2005 · Primary completion Jan 2008
Drug: Alfuzosin; Placebo · For: Prostatitis
Sites: Los Angeles, California; Stanford, California; Chicago, Illinois · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness252
- drug ineffective206
- fatigue200
- dyspnoea145
- asthenia132
- nausea132
- fall126
- diarrhoea124
- headache119
- hypotension102
- syncope97
- insomnia94
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 279 |
| 2005 | 270 |
| 2006 | 180 |
| 2007 | 129 |
| 2008 | 140 |
| 2009 | 183 |
| 2010 | 301 |
| 2011 | 312 |
| 2012 | 275 |
| 2013 | 103 |
| 2014 | 87 |
| 2015 | 177 |
| 2016 | 196 |
| 2017 | 163 |
| 2018 | 127 |
| 2019 | 102 |
| 2020 | 117 |
| 2021 | 95 |
| 2022 | 30 |
| 2023 | 23 |
| 2024 | 31 |
| 2025 | 32 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Uroxatral (Alfuzosin HCl)
2024 spending
$1.7M
Beneficiaries
231
1,045 claims
Per beneficiary
$7,446
$25.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,045,196 |
| 2021 | $1,881,630 |
| 2022 | $1,917,293 |
| 2023 | $1,932,243 |
| 2024 | $1,720,101 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- New alpha blockers to treat male lower urinary tract symptoms.
Hwang EC, Gandhi S, Jung JH · Curr Opin Urol 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Buzelin JM, Fonteyne E, Kontturi M, et al. · Br J Urol 1997 · Clinical Trial, Clinical Trial, Phase III
- Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy.
Lee SW, Liong ML, Yuen KH, et al. · Urol Int 2007 · Systematic Review
- The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
Van Kerrebroeck PE · Eur Urol 2001 · Clinical Trial, Randomized Controlled Trial
- Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. · Lancet 1991 · Clinical Trial, Multicenter Study
- Comorbid LUTS and erectile dysfunction: optimizing their management.
Kaminetsky J · Curr Med Res Opin 2006 · Systematic Review
Sponsor: Advanz Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.